The combined detection of carcinoembryonic antigen, carcinogenic antigen 125, and carcinogenic antigen 19-9 in colorectal cancer patients

Table 1 Comparison of general information between the two groups of patients, mean ± SD

Feature	Simple colorectal cancer group (n = 50)	Colorectal cancer with liver metastasis group (n = 50)	P value
Age (yr)	61.48 ± 12.81	63.63 ± 11.67	0.243
Gender (Male/Female)	28/22	29/21	0.862

Table 2 Comparison of serum carcinoembryonic antigen, cancer antigen 125 and cancer antigen 19-9 levels between two groups of patients, mean ± SD

Serum markers	Simple colorectal cancer group (n = 50)	Colorectal cancer with liver metastasis group (n = 50)	t	P value
CEA (ng/mL)	5.71 ± 9.76	162.03 ± 810.01	-1.81	0.72
CA125 (U/mL)	13.5 ± 19.68	43.47 ± 83.52	-3.28	0.01
CA19-9 (U/mL)	26.55 ± 43.96	184.46 ± 473.13	-3.1	0.02

CEA: Carcinoembryonic antigen; CA: Cancer antigen.

Table 3 Binary logistic regression analysis results

Serum markers	Score	P value
CEA (ng/mL)	2.906	0.088
CA125 (U/mL)	9.755	0.002
CA19-9 (U/mL)	7.39	0.007

CEA: Carcinoembryonic antigen; CA: Cancer antigen.

Table 4 Receiver operating characteristic analysis results

Serum markers	Area	Critical value	Sensitivity	95%CI
CEA (ng/mL)	0.607	0.043	0.014	0.523-0.691
CA125 (U/mL)	0.692	0.04	0	0.613-0.77
CA19-9 (U/mL)	0.586	0.043	0.049	0.502-0.671

CEA: Carcinoembryonic antigen; CA: Cancer antigen.